Deficient mismatch repair as a prognostic marker in stage II colon cancer patients
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Multicenter Study
PubMed
31186203
DOI
10.1016/j.ejso.2019.05.023
PII: S0748-7983(19)30461-5
Knihovny.cz E-resources
- Keywords
- Colon cancer, Prognostic factors, Stage II, dMMR,
- MeSH
- Adenocarcinoma diagnosis genetics metabolism MeSH
- DNA, Neoplasm genetics MeSH
- Adult MeSH
- Immunohistochemistry MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Colonic Neoplasms diagnosis genetics therapy MeSH
- Follow-Up Studies MeSH
- DNA Mismatch Repair * MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Names of Substances
- DNA, Neoplasm MeSH
BACKGROUND: A number of reports have evaluated the relationship between deficient DNA mismatch repair (dMMR) and colorectal cancer prognosis. Unfortunately, the exact prognostic role of dMMR has not been clearly established due to contradictory results. This study aims to determine the prognostic impact of dMRR in stage II colon cancer patients only. The appropriate identification of high-risk stage II colon cancers is of paramount importance in the selection of patients who may benefit from adjuvant treatment after surgery. METHODS: Four hundred and fifty-two patients with curative resection of stage II colon cancer were included. Hospital records were used as data source, providing clinical, surgical, pathology, oncology and follow-up information for statistical analysis focusing on overall survival (OS) and time to progression (TTP). Mismatch repair status was determined by immunohistochemistry. Patient survival was followed-up for a mean of 77·35 months. RESULTS: dMMR was detected in 93 of 452 patients (20·6%). No impact on overall survival (Log-Rank, p = 0·583, 95% CI 0·76-1·67). However, the hazard ratio 0·50 for TTP was highly significant (Log-Rank, p = 0·012, 95% CI 0·28-0·87) in patients with dMMR compared with those with mismatch repair proficient tumours (pMMR). CONCLUSIONS: Patients with dMMR tumours have a lower risk for recurrence compared to those with pMMR tumours, but this finding did not correlate to better overall survival.
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Medical Biosciences Pathology Umeå University Umeå Sweden
Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Surgery University Hospital Kralovske Vinohrady Prague Czech Republic
Department of Surgical and Perioperative Sciences Umeå University Umeå Sweden
Faculty Hospital Pilsen Charles University Prague Czech Republic
References provided by Crossref.org
